Inify Laboratories

Mindre end 1K følgere

INIFY

Euronext Growth Oslo

Medical Equipment & Services

Health Care

Oversigt

Investorkonsensus

Inify Laboratories provides cancer diagnostics through pathology laboratory services. The company uses a digital, standardized workflow for response times and quality assurance, initially in prostate diagnostics. Customers primarily consist of laboratories and hospitals. Inify Laboratories was founded in 2022 and is headquartered in Stockholm, Sweden.

Markedsværdi

-

Aktieomsætning

-

Omsætning

13,5 mio.

EBIT %

-403,58 %

P/E

-

Udbytteafkast, %

-

Finanskalender

25.2

2026

Årsrapport '25

29.4

2026

Delårsrapport Q1'26

20.5

2026

Generalforsamling '26

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse4.12.2025, 12.07

INIFY: Bulletin from the extraordinary general meeting of Inify Laboratories AB

Inify Laboratories

Selskabsmeddelelse4.12.2025, 12.06

Bulletin from the extraordinary general meeting of Inify Laboratories AB

Inify Laboratories

Selskabsmeddelelse3.12.2025, 12.30

Inify Laboratories: Board announces updated timetable for settlement in proposed Private Placement and Repair Issue

Inify Laboratories

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse3.12.2025, 12.30

Inify Laboratories AB: Inify Laboratories: Board announces updated timetable for settlement in proposed Private Placement and Repair Issue

Inify Laboratories

Selskabsmeddelelse28.11.2025, 09.57

INIFY: Financial calendar

Inify Laboratories

Selskabsmeddelelse12.11.2025, 14.09

Inify Laboratories - notice of Extraordinary General Meeting on December 4, 2025

Inify Laboratories

Selskabsmeddelelse12.11.2025, 14.09

Inify Laboratories AB: Inify Laboratories - notice of Extraordinary General Meeting on December 4, 2025

Inify Laboratories

Selskabsmeddelelse12.11.2025, 09.50

Inify Laboratories: Notice of Extraordinary General Meeting and proposed fully guaranteed equity issue with proceeds of NOK 100 million

Inify Laboratories

Selskabsmeddelelse12.11.2025, 09.50

Inify Laboratories AB: Inify Laboratories: Notice of Extraordinary General Meeting and proposed fully guaranteed equity issue with proceeds of NOK 100 million

Inify Laboratories

Selskabsmeddelelse29.10.2025, 10.15

Correction - Inify Laboratories: First gastrointestinal diagnoses delivered and UK clinical operations on track for launch early 2026

Inify Laboratories

Selskabsmeddelelse29.10.2025, 10.15

Inify Laboratories AB: Correction - Inify Laboratories: First gastrointestinal diagnoses delivered and UK clinical operations on track for launch early 2026

Inify Laboratories

Selskabsmeddelelse29.10.2025, 07.00

Inify Laboratories: First gastrointestinal diagnoses delivered and UK clinical operations on track for launch early 2026

Inify Laboratories

Selskabsmeddelelse29.10.2025, 07.00

Inify Laboratories AB: Inify Laboratories: First gastrointestinal diagnoses delivered and UK clinical operations on track for launch early 2026

Inify Laboratories

Selskabsmeddelelse29.8.2025, 09.56

Inify Laboratories - mandatory notification of trade

Inify Laboratories

Selskabsmeddelelse29.8.2025, 09.56

Inify Laboratories AB: Inify Laboratories - mandatory notification of trade

Inify Laboratories

Selskabsmeddelelse27.8.2025, 06.00

Inify Laboratories: Solid growth in Sweden and first patient diagnostics delivered in the UK

Inify Laboratories

Selskabsmeddelelse27.8.2025, 06.00

Inify Laboratories AB: Inify Laboratories: Solid growth in Sweden and first patient diagnostics delivered in the UK

Inify Laboratories

Selskabsmeddelelse21.5.2025, 06.00

Inify Laboratories AB (publ) - summary of Annual General Meeting

Inify Laboratories

Selskabsmeddelelse21.5.2025, 06.00

Inify Laboratories AB (publ) - summary of Annual General Meeting

Inify Laboratories

Selskabsmeddelelse30.4.2025, 06.00

Inify Laboratories: Continued strong growth - construction and establishment in the UK

Inify Laboratories

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.